reports
Integra LifeSciences to Spotlight CereLink® Intracranial Pressure (ICP...
Integra LifeSciences to Spotlight CereLink® Intracranial Pressure (ICP) Monitoring System at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting Visit the Codman Specialty Surgical booth to learn how the CereLink ICP Monitoring System provides patients with uncompromised advanced continuous ICP monitoring. PRINCETON, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, is pleased to announce that following a successful Q1 2024 U.S. relaunch of its , the innovative product will be featured at the upcoming AA...
Integra LifeSciences to Reschedule the First Quarter 2024 Financial Re...
Integra LifeSciences to Reschedule the First Quarter 2024 Financial Results Conference Call to May 6, 2024 PRINCETON, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, today announced that it has rescheduled the release of the Company’s first quarter 2024 financial results to Monday, May 6, 2024. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. EDT. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on the ...
Integra LifeSciences Completes the Acquisition of Acclarent, Inc.
Integra LifeSciences Completes the Acquisition of Acclarent, Inc. PRINCETON, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of , a pioneer in ear, nose and throat (ENT) surgical interventions. The addition of Acclarent's innovative product portfolio expands the breadth of Integra’s market-leading brands and provides immediate scale and accretive growth via a dedicated sales channel. The acquisition adds $1 billion to the total addressable market of the Company’s offerings, ...
Integra LifeSciences Launches MicroMatrix® Flex to Provide Convenient ...
Integra LifeSciences Launches MicroMatrix® Flex to Provide Convenient Access to Hard-to-Reach Areas in Complex Cases Novel system features flexible tip to deliver flowable version of the Urinary Bladder Matrix (UBM) technology PRINCETON, N.J., March 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq:IART), today announced MicroMatrix® Flex is now available commercially in the U.S. MicroMatrix Flex is a dual-syringe system enabling the convenient mixing and precise delivery of MicroMatrix® paste to provide convenient access to hard-to-reach spaces and to help prepare an even wound surface in challeng...
Integra LifeSciences Reports Fourth Quarter and Full-Year 2023 Financi...
Integra LifeSciences Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Reported revenues were $397.0 million, representing a decrease of 0.2% on a reported basis and a decrease of 1.2% on an organic basis compared to the fourth quarter 2022. Revenue increased 3.6% on an organic basis excluding Boston. GAAP earnings per d...
Integra LifeSciences Announces Leadership Transition Plan
Integra LifeSciences Announces Leadership Transition Plan Jan De Witte to retire as CEO by the end of 2024Stuart Essig appointed executive chairman of the Board PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- (“Integra” or “the Company”) (NASDAQ: IART), a leading global medical technology company, today announced that Jan De Witte has informed the Board of Directors (the “Board”) of his intention to retire from his position as president and chief executive officer of Integra following the appointment of a successor, which the Company expects to occur by the end of 2024. The Compa...
Integra LifeSciences to Host Fourth Quarter and Full Year 2023 Financi...
Integra LifeSciences to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024 PRINCETON, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on t...
- Valens Research
Valens Equity Weekly Insights - 2024 01 09
Integra Lifesciences (IART) announced recalls for two of its products since August 2022. The market appears to think this is a sign of more issues to come and doesn't understand it's the company drawing a line under quality control issues, as it brings in new leadership. Uniform Accounting shows that the market is overly pessimistic about this company, indicating equity upside. Integra is one of the leaders in the medical technology industry, specifically in the fields of regenerative medicine ...
Integra LifeSciences to Present at the 42nd Annual J.P. Morgan Healthc...
Integra LifeSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference PRINCETON, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, announced today that Jan De Witte, president and chief executive officer will present at the 42nd Annual J.P. Morgan Healthcare conference on January 10, 2024 at 1:30pm ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website at . About Integra LifeSciencesAt Integra LifeSciences, we are driven by our purpose of restoring patients’ lives....
Integra LifeSciences Announces Definitive Agreement to Acquire Acclare...
Integra LifeSciences Announces Definitive Agreement to Acquire Acclarent® The acquisition will become part of Integra’s Codman Specialty Surgical (CSS) division. The ear, nose and throat (ENT) category is a key area of strategic interest and highly complementary to the neurosurgery segment.Provides a unique opportunity to build scale and capture a leadership position in the attractive ENT device segment with Acclarent’s established commercial scale, strong brand recognition, differentiated portfolio, and robust innovation pipeline. Generates shareholder value; transaction expected to be ...
Integra LifeSciences Appoints Jeff Graves, Ph.D., to Board of Director...
Integra LifeSciences Appoints Jeff Graves, Ph.D., to Board of Directors PRINCETON, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, today announced that Jeff Graves, Ph.D., president and chief executive officer of 3D Systems Corporation, was appointed to the company’s board of directors, effective immediately. With the appointment of Dr. Graves, Integra has added four new directors since 2021. “I am pleased to welcome Jeff to our board of directors. He is a highly-accomplished executive with a track record of leading and transforming...
Integra LifeSciences Reports Third Quarter 2023 Financial Results
Integra LifeSciences Reports Third Quarter 2023 Financial Results PRINCETON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2023. Third Quarter 2023 Highlights Third quarter revenues of $382.4 million declined 0.7% on a reported basis and declined 0.4% on an organic basis compared to the prior year and increased 7.1% on an organic basis excluding BostonThird quarter GAAP earnings per diluted share of $0.24, compared to $0.60 in the prior year; adjusted earni...
- Valens Research
Valens Equity Weekly Insights - 2023 10 10
Integra Lifesciences (IART) announced recalls for two of its products since August 2022. The market appears to think this is a sign of more issues to come and doesn't understand it's the company drawing a line under quality control issues, as it brings in new leadership. Uniform Accounting shows that the market is overly pessimistic about this company, indicating equity upside. Integra is one of the leaders in the medical technology industry, specifically in the fields of regenerative medicine ...
Integra LifeSciences to Host Third Quarter 2023 Financial Results Conf...
Integra LifeSciences to Host Third Quarter 2023 Financial Results Conference Call on October 25, 2023 PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, will release third quarter 2023 financial results on Wednesday, October 25, 2023, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on the call, register to receive ...
Integra LifeSciences to Present at the 2023 Wells Fargo Healthcare Con...
Integra LifeSciences to Present at the 2023 Wells Fargo Healthcare Conference PRINCETON, N.J., Sept. 01, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer will present at the 2023 Wells Fargo Healthcare Conference on September 6, 2023 at 1:30 p.m. EST. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website at . About Integra LifeSciencesAt Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment p...
Integra LifeSciences Reports Second Quarter 2023 Financial Results
Integra LifeSciences Reports Second Quarter 2023 Financial Results PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2023. Second Quarter 2023 Highlights Second quarter revenues of $381.3 million declined 4.2% on a reported basis and declined 2.7% on an organic basis compared to the prior year. Second quarter GAAP earnings per diluted share of $0.05, compared to $0.54 in the prior year; adjusted earnings per dilu...
- Valens Research
Valens Equity Weekly Insights - 2023 07 25
Integra Lifesciences (IART) announced recalls for two of its products since August 2022. The market appears to think this is a sign of more issues to come and doesn't understand it's the company drawing a line under quality control issues, as it brings in new leadership. Uniform Accounting shows that the market is overly pessimistic about this company, indicating equity upside. Integra is one of the leaders in the medical technology industry, specifically in the fields of regenerative medicine ...
Integra LifeSciences to Host Second Quarter 2023 Financial Results Con...
Integra LifeSciences to Host Second Quarter 2023 Financial Results Conference Call on July 27, 2023 PRINCETON, N.J., July 03, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, will release second quarter 2023 financial results on Thursday, July 27, 2023, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on the call, register to receive dial-...
Integra LifeSciences Announces Complete Enrollment in DuraSorb® Monofi...
Integra LifeSciences Announces Complete Enrollment in DuraSorb® Monofilament Mesh U.S. IDE Study Achieves Significant Milestone on Pathway to PMA Approval for Two-Stage Breast Reconstruction PRINCETON, N.J., June 28, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq:IART), a leading global medical technology company, announced the completion of patient enrollment in the DuraSorb U.S. investigational device exemption (IDE) clinical study for two-stage breast reconstruction. is a bioabsorbable matrix currently 510(K) cleared for the reinforcement of soft tissue wh...
Integra LifeSciences Appoints Lea Daniels Knight, Executive Vice Presi...
Integra LifeSciences Appoints Lea Daniels Knight, Executive Vice President and Chief Financial Officer PRINCETON, N.J., June 21, 2023 (GLOBE NEWSWIRE) -- (Nasdaq:IART) today announced the appointment of Lea Daniels Knight as executive vice president and chief financial officer, effective June 28, 2023. Ms. Knight has over 30 years of experience in global companies with significant operating scale and complexity, leading and developing high-performing teams, and demonstrating success in combining financial acumen and business process leadership with strategic vision to deliver strong bu...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.